Browse EDEM3

Summary
SymbolEDEM3
NameER degradation enhancer, mannosidase alpha-like 3
Aliases C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum lumen
Domain PF01532 Glycosyl hydrolase family 47
PF02225 PA domain
Function

Involved in endoplasmic reticulum-associated degradation (ERAD). Accelerates the glycoprotein ERAD by proteasomes, by catalyzing mannose trimming from Man8GlcNAc2 to Man7GlcNAc2 in the N-glycans. Seems to have alpha 1,2-mannosidase activity (By similarity).

> Gene Ontology
 
Biological Process GO:0006486 protein glycosylation
GO:0006487 protein N-linked glycosylation
GO:0006491 N-glycan processing
GO:0006516 glycoprotein catabolic process
GO:0006517 protein deglycosylation
GO:0006986 response to unfolded protein
GO:0009100 glycoprotein metabolic process
GO:0009101 glycoprotein biosynthetic process
GO:0009311 oligosaccharide metabolic process
GO:0010498 proteasomal protein catabolic process
GO:0030433 ER-associated ubiquitin-dependent protein catabolic process
GO:0030968 endoplasmic reticulum unfolded protein response
GO:0034620 cellular response to unfolded protein
GO:0034976 response to endoplasmic reticulum stress
GO:0035966 response to topologically incorrect protein
GO:0035967 cellular response to topologically incorrect protein
GO:0035977 protein deglycosylation involved in glycoprotein catabolic process
GO:0036503 ERAD pathway
GO:0036507 protein demannosylation
GO:0036508 protein alpha-1,2-demannosylation
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
GO:0043413 macromolecule glycosylation
GO:0044723 single-organism carbohydrate metabolic process
GO:0070085 glycosylation
GO:0097466 glycoprotein ERAD pathway
GO:1901136 carbohydrate derivative catabolic process
GO:1904380 endoplasmic reticulum mannose trimming
GO:1904382 mannose trimming involved in glycoprotein ERAD pathway
GO:1904587 response to glycoprotein
Molecular Function GO:0004553 hydrolase activity, hydrolyzing O-glycosyl compounds
GO:0004559 alpha-mannosidase activity
GO:0004569 glycoprotein endo-alpha-1,2-mannosidase activity
GO:0004571 mannosyl-oligosaccharide 1,2-alpha-mannosidase activity
GO:0015923 mannosidase activity
GO:0015924 mannosyl-oligosaccharide mannosidase activity
GO:0016798 hydrolase activity, acting on glycosyl bonds
Cellular Component GO:0005788 endoplasmic reticulum lumen
GO:0044322 endoplasmic reticulum quality control compartment
> KEGG and Reactome Pathway
 
KEGG hsa04141 Protein processing in endoplasmic reticulum
Reactome R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-901042: Calnexin/calreticulin cycle
R-HSA-901032: ER Quality Control Compartment (ERQC)
R-HSA-392499: Metabolism of proteins
R-HSA-532668: N-glycan trimming in the ER and Calnexin/Calreticulin cycle
R-HSA-597592: Post-translational protein modification
Summary
SymbolEDEM3
NameER degradation enhancer, mannosidase alpha-like 3
Aliases C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between EDEM3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolEDEM3
NameER degradation enhancer, mannosidase alpha-like 3
Aliases C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of EDEM3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: 1.35; FDR: 0.000150 Sensitive to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolEDEM3
NameER degradation enhancer, mannosidase alpha-like 3
Aliases C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of EDEM3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4220.135
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4460.782
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4020.729
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0630.843
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0610.975
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2240.932
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2370.576
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0320.986
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.5450.786
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4360.707
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9320.582
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0370.509
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of EDEM3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.17.71.41
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolEDEM3
NameER degradation enhancer, mannosidase alpha-like 3
Aliases C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EDEM3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolEDEM3
NameER degradation enhancer, mannosidase alpha-like 3
Aliases C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EDEM3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EDEM3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolEDEM3
NameER degradation enhancer, mannosidase alpha-like 3
Aliases C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EDEM3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolEDEM3
NameER degradation enhancer, mannosidase alpha-like 3
Aliases C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of EDEM3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolEDEM3
NameER degradation enhancer, mannosidase alpha-like 3
Aliases C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between EDEM3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolEDEM3
NameER degradation enhancer, mannosidase alpha-like 3
Aliases C1orf22; chromosome 1 open reading frame 22; ER degradation-enhancing -mannosidase-like protein 3; ER degrad ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting EDEM3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.